{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:23:05Z","timestamp":1793312585987,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.cgh.2024.11.013","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T16:04:40Z","timestamp":1734365080000},"page":"1387-1397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Rothenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy J.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Ting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan S.","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Keir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Panes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2024.11.013_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.gastrohep.2023.04.001","article-title":"Leishmania infection in patients with inflammatory bowel disease: case series and literature review","volume":"47","author":"Gimeno-Pitarch","year":"2024","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.11.013_bib2","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.11.013_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.trsl.2021.06.001","article-title":"Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier","volume":"236","author":"Liu","year":"2021","journal-title":"Transl Res"},{"key":"10.1016\/j.cgh.2024.11.013_bib4","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192195","article-title":"The role of IL-22 in intestinal health and disease","volume":"217","author":"Keir","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.cgh.2024.11.013_bib5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.intimp.2004.01.016","article-title":"IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues","volume":"4","author":"Gurney","year":"2004","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.cgh.2024.11.013_bib6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1136\/gutjnl-2022-328387","article-title":"Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis","volume":"72","author":"Wagner","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.11.013_bib7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/00054725-200305000-00003","article-title":"Increased expression of HIP\/PAP and regenerating gene III in human inflammatory bowel disease and a murine bacterial reconstitution model","volume":"9","author":"Ogawa","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.11.013_bib8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1515\/bc.2010.101","article-title":"Isolation of genes involved in pancreas regeneration by subtractive hybridization","volume":"391","author":"Choi","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.cgh.2024.11.013_bib9","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.4049\/jimmunol.178.9.5973","article-title":"IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease","volume":"178","author":"Wolk","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2024.11.013_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/hep.24339","article-title":"In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression","volume":"54","author":"Park","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2024.11.013_bib11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3109\/00365529209011186","article-title":"Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study","volume":"27","author":"Roseth","year":"1992","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.11.013_bib12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2024.11.013_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cpt.1164","article-title":"Randomized phase I healthy volunteer study of UTTR1147A (IL-22Fc): a potential therapy for epithelial injury","volume":"105","author":"Rothenberg","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.11.013_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10928-023-09888-2","article-title":"Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)","volume":"51","author":"Yu","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.cgh.2024.11.013_bib15","first-page":"197","article-title":"Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis","volume":"30","author":"Kapel","year":"1992","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"10.1016\/j.cgh.2024.11.013_bib16","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524010966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524010966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:13:05Z","timestamp":1762549985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356524010966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1542356524010966"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2024.11.013","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2024.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}